Iovance Biotherapeutics Inc Provides Update for Lifileucel in Metastatic Melanoma- Corporate Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Iovance Biotherapeutics Regulatory Update. (Operator Instructions)
I will now hand the conference over to your speaker today, Ms. Sara Pellegrino. Please go ahead.
Thank you, operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Maria Fardis, our President and Chief Executive Officer. This afternoon, we issued a press release that can be found on our website at iovance.com, which includes a regulatory update.
Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans, pre-commercial activities, clinical trial plans and results, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, collaborations, cash position and expense guidance and future updates.
Forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
